09:15 AM EST, 12/03/2024 (MT Newswires) -- Immunocore Holdings ( IMCR ) said Tuesday that the National Institute for Health and Care Excellence has recommended Kimmtrak for funding through the National Health Service in England.

The National Institute for Health recommended Kimmtrak within its marketing authorization to treat adults with unresectable or metastatic uveal melanoma, the company said, adding that the NICE initially declared a "negative decision" in May last year for Kimmtrak, which Immunocore ( IMCR ) appealed in December 2023.

Kimmtrak is now funded on the National Health Service in England as of Dec. 2, the company said.

Shares of the company were up 2.7% in recent Tuesday premarket activity.